IGF-1 LR3

Long R3 insulin-like growth factor 1 analogue engineered for prolonged activity, reduced IGF-binding protein affinity and enhanced IGF‑1 receptor signalling in research models.

Evidence: Mechanistic / Limited Human Function: Anabolic & Growth Signalling Class: IGF-1 analogue (Long R3)

Explore calculators for this peptide

Use the Peptide Research Tools to experiment with reconstitution, mg/kg ranges and simplified half-life curves for IGF-1 LR3. All values are placeholders and must be aligned with your own research protocol.

Open IGF-1 LR3 in calculators →

Research frame & potential applications

IGF‑1 LR3 is a modified 83‑amino‑acid IGF‑1 analogue featuring an arginine substitution at position 3 and an extended N‑terminal sequence, drastically reducing affinity for IGF‑binding proteins and extending functional half‑life. These changes allow sustained IGF‑1 receptor activation and make IGF‑1 LR3 a powerful research tool for probing muscle hypertrophy, metabolic signalling, neuroplasticity, tissue regeneration and oncogenic pathways under prolonged IGF‑like drive.

Research areas & putative benefits

Where IGF‑1 LR3 is used to interrogate growth, metabolism and repair.

Muscle hypertrophy and atrophy models, examining satellite cell activation, fibre size and recovery after injury or unloading.
Metabolic signalling research, including insulin‑sensitising or desensitising effects, glucose uptake and lipid handling in various tissues.
Neuroplasticity and neuroprotection paradigms, exploring survival, neurite outgrowth and synaptic plasticity under enhanced IGF‑1 signalling.
Oncology and proliferative disease models, assessing how sustained IGF‑1 pathway activation influences tumour growth, survival and resistance mechanisms.

Mechanism stack

Core molecular properties and signalling pathways engaged by IGF‑1 LR3.

Structure

Arg3 substitution + N-terminal extension

IGF‑1 LR3 incorporates an arginine at position 3 and a 13‑amino‑acid N‑terminal tail, reducing IGF‑binding protein affinity by orders of magnitude and extending receptor‑active half‑life to roughly 20–30 hours in many models.

Receptor binding

IGF-1R activation

The analogue binds IGF‑1 receptors with high affinity, driving canonical downstream pathways including PI3K/Akt/mTOR for growth and survival and MAPK/ERK for proliferation and differentiation.

Functional profile

Sustained anabolic signalling

Reduced sequestration by IGFBPs leaves more free ligand to stimulate receptors, amplifying and prolonging anabolic, neurotrophic and metabolic effects compared with native IGF‑1 under similar exposure conditions.

Risk axis

Mitogenic & oncogenic potential

The same proliferative and anti‑apoptotic signalling that supports repair and growth also intersects with pathways implicated in tumour initiation, growth and therapy resistance, central to IGF‑1 LR3 risk considerations.

Evidence snapshot

Selected findings from IGF‑1 LR3 cellular, animal and translational research.

Model / context	Observation	Notes
Cell culture models In vitro	IGF‑1 LR3 promotes proliferation, survival and differentiation across myocytes, neurons and other cell types more potently than equimolar native IGF‑1 due to prolonged free ligand availability.	Useful for dissecting IGF‑1R pathway sensitivity, feedback and desensitisation mechanisms.
Skeletal muscle models Preclinical muscle	In animal models, sustained IGF‑1 analogue exposure has been associated with increased muscle mass, fibre cross‑sectional area and improved recovery from injury, alongside context‑dependent metabolic changes.	Highlights powerful anabolic potential but also raises questions about disproportionate organ growth and long‑term systemic effects.
Organ growth & systemic effects Whole-organism	Chronic infusion of long‑acting IGF‑1 variants in animals can enlarge multiple organs and alter cardiac and metabolic parameters, echoing features of acromegalic physiology.	Underlines the need for cautious, research‑only framing and careful dose–response mapping.
Oncology & tumour models Oncogenic interface	IGF‑1 pathway activation is implicated in tumour cell survival, proliferation and resistance to some therapies; IGF‑1 LR3 can be used to stress‑test these pathways in vitro and in vivo.	Raises theoretical concern that uncontrolled or off‑label use may amplify latent oncogenic processes.

Risk frame & unknowns

Major caveats for interpreting IGF‑1 LR3 research and any off‑label experimentation.

Important research caveats

IGF‑1 is a central growth and survival factor; chronic enhancement of its signalling may contribute to organ enlargement, insulin axis disruption and tumour promotion.
Human data for IGF‑1 LR3 specifically are limited, with most knowledge extrapolated from native IGF‑1 biology and animal work.
Precise dosing windows that separate regenerative benefits from mitogenic risk are not well defined in humans.
Use outside formal research or carefully controlled clinical trials is particularly concerning given the axis’s tight integration with oncogenic pathways.

This dossier summarizes mechanistic, preclinical and limited translational findings on IGF‑1 LR3 for scientific and educational purposes only. It does not provide medical advice, treatment guidance or dosing recommendations.